论文部分内容阅读
目的:探讨Ⅱ型糖尿病患者经皮冠状动脉介入术后氯吡格雷抵抗现象。方法:入院急性冠脉综合征(ACS)患者46例,其中糖尿病患者11例,非糖尿病患者35例,予氯吡格雷负荷量300 mg,继予75 mg/d维持,在服用氯吡格雷前,服药后2、4、6、24、48与30 d取血,测定5μmol/L二磷酸腺苷(ADP)诱导的血小板聚集率,分析两组间临床特征、血小板抑制率的差异。结果:糖尿病患者11例中氯吡格雷抵抗的发生率为55%,高于非糖尿病患者26%(P<0.05)。结论:在经PCI治疗的ACS并发Ⅱ型糖尿病患者中氯吡格雷抵抗的发生率高于非糖尿病患者。
Objective: To investigate the clopidogrel resistance in patients with type 2 diabetes mellitus after percutaneous coronary intervention. METHODS: Forty-six patients with acute coronary syndrome (ACS) admitted to hospital were enrolled in this study. Among them, 11 patients with diabetes and 35 patients without diabetes received clopidogrel loading of 300 mg, followed by 75 mg / d. Before taking clopidogrel The blood samples were taken at 2, 4, 6, 24, 48 and 30 d after treatment. The platelet aggregation rate induced by 5 μmol / L adenosine diphosphate (ADP) was measured. The difference of clinical features and platelet inhibition rate between the two groups was analyzed. Results: The incidence of clopidogrel resistance in 11 patients with diabetes was 55%, which was higher than that in non-diabetic patients (P <0.05). Conclusion: The incidence of clopidogrel resistance in patients with type 2 diabetes mellitus complicated with PCI is higher than that in non-diabetic patients.